• Increase font size
  • Default font size
  • Decrease font size
home | about us | contact us
Search
Search Only:

Search Keyword cytori

Total: 50 results found.

... 2008, is $15.6 million, including an increase in the first milestone-based option, which was exercised in September 2009. Cytori Therapeutics (NASDAQ: CYTX) has received European (CE Mark) approval for ...
... in urinary incontinence episodes for both doses studied. An Open Label Extension study, evaluating long term safety remains ongoing and is scheduled to complete by Q4 2010. Cytori Therapeutics (NASDAQ: ...
... BrainStorm Cell Therapeutics 5.5.7 Cytori Therapeutics 5.5.8 ...
... will be operated out of Dallas by BioLife Cell Bank, LLC, utilizing the StemSource® Cell Bank equipment from Cytori Therapeutics. This is the fourth StemSource® Cell Bank to be installed worldwide ...
... or 73 cents, closing the day at $2.94. Cytori Therapeutics (NASDAQ: CYTX) rose higher today after the company reported that it has entered into a $20 million secured loan facility from GE Capital, Healthcare ...
... markets and expanding its geographic reach." Cytori Therapeutics (NASDAQ: CYTX) has sold its first StemSource Cell Bank in the United States. The StemSource Cell Bank is a suite of products that offers ...
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) has sold its first StemSource® Cell Bank in the United States. The StemSource® Cell Bank is a suite of products that offers patiens a ...
... from a single investor, Seaside 88, LP (“Seaside”), a Florida limited partnership. Seaside has financed several leading-edge bio-pharma companies, including Cytori Therapeutics, Inc., Generex Biotechnology ...
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present and provide a webcast of their corporate presentation at MDB Capital Bright Lights Conference at 5:30 PM (EDT) onWednesday, ...
... and feasibility outcomes, and the biological, physiological and functional effects from this pilot study, plans are underway by Cytori Therapeutics (NASDAQ: CYTX - News), the trial sponsor, to initiate ...
... device developed by trial sponsor Cytori Therapeutics (NASDAQ:CYTX). More detailed information on this study and the results from a separate study in heart attack patients also reported today may be ...
...  Cytori Therapeutics Inc. (CYTX; Xetra:XMPA) Depomed Inc. (DEPO) Dyax Corp. (DYAX) Enobia Pharma Inc. Exact Sciences Corp. (EXAS) Five Prime Therapeutics Inc. Gemin X Pharmaceuticals Inc. GlobeImmune ...
...  Cytori Therapeutics Inc. (CYTX: XMPA); XETRA: XMPA) Depomed Inc. (DEPO) Dyax Corp. (DYAX) Enobia Pharma Inc. Exact Sciences Corp. (EXAS) Five Prime Therapeutics Inc. Gemin X Pharmaceuticals ...
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present and provide a webcast of their corporate presentation at BioCentury’s Future Leaders in the Biotech Industry coference ...
... for Regenerative Medicine, Celgene Cellular, Cellerant, Cleveland Clinic, Corning, Cytori, Fate Therapeutics, Genetics Policy Institute, Geron Corporation, International Stem Cell Corporation, iPierian, ...
... testing required in support of the previously filed vessel sealing instrument 510(k) application. Cytori Therapeutics (NASDAQ:CYTX ) the maker of products used in adult stem cell harvesting and research, ...
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX) is reporting its financial results for the year ended December 31, 2009. More information on our commercial and clinical progress isosted ...
... Cytori Therapeutics, Pluristem Therapeutics and Geron. The report will enhance your decision making capability. It will allow you to: Develop and design your in-licensing and out-licensing strategies ...
... Inc. (CYCC): Biotechnology & Healthcare Cypress Bioscience, Inc. (CYPB): Pharmaceuticals Cytori Therapeutics, Inc. (CYTX): Medical Devices CytRx Corporation (CYTR): Biotechnology & Healthcare ...
... Corporation (CYDE): Business Services Cyclacel Pharma Inc. (CYCC): Biotechnology & Healthcare Cypress Bioscience, Inc. (CYPB): Pharmaceuticals Cytori Therapeutics, Inc. (CYTX): Medical Devices ...
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces their spring 2010 medical and investor conference schedule. The full schedule may be accessed from the following linkin the ...
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) will host a webcast to discuss their year-end and fourth quarter financial results on Friday, March 12, 2010 at 10:30 AM Eastern Tim. Prior ...
...  Corporation (CYDE): Business ServicesCyclacel Pharma Inc. (CYCC): Biotechnology & HealthcareCypress Bioscience, Inc. (CYPB): PharmaceuticalsCytori Therapeutics, Inc. (CYTX): Medical DevicesCytRx ...
... Media & Internet Cyclacel Pharma Inc. (CYCC): Biotechnology & Healthcare Cypress Bioscience, Inc. (CYPB): Pharmaceuticals Cytori Therapeutics, Inc. (CYTX): Medical Devices CytRx Corporation ...
... forth by the NJ program. Array BioPharma Inc. (NASDAQ: ARRY) today announced that Bengt Bergstrom, M.D., has joined the Company as Vice President of Clinical Development. Cytori Therapeutics (NASDAQ:CYTX) ...
... with analysts and investors to discuss its fourth quarter 2009 financial results. Cytori Therapeutics (NASDAQ:CYTX) announced today that it had received U.S. Patent No. 7,651,684 (the ‘684 patent) which ...
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX) today received U.S. Patent No. 7,651,684 (the ‘684 patent) which covers the Company’s methods for delivering adipose-deried stem ...
SAN DIEGO--(BUSINESS WIRE)--Results from Cytori Therapeutics’ (NASDAQ: CYTX) preclinical fat grafting study have been published in the February issue of the Annals of Plastic Surgery. Thisrticle, ...
... of various medical devices from Cytori Therapeutics, Inc. SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced ...
... subsidiary, has provided the first tranche of financing to Stem Cell for the purchase of various medical devices from Cytori Therapeutics, Inc. In addition, MDwerks, through its subsidiary Digital ...
... and stated that a FDA decision is still pending for Xiaflex. On 9/16/09, the FDA Panel voted 12-0 in favor of Xiaflex to treat Dupuytren's disease. On 7/17/09, Cytori Therapeutics (NASDAQ: CYTX) announced ...
On 1/7/10, the FDA granted marketing clearance to Cytori Therapeutics (NASDAQ: CYTX) for the PureGraft System, which will be launched as the first and only device in the US cleared for aesthetic body contouring ...
Cytori Therapeutics (NASDAQ: CYTX) is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating ...
...  On 7/17/09, Cytori Therapeutics (NASDAQ: CYTX) (click on preceding link for Cytori's ProActive News Room landing page) announced that the FDA will regulate the Company's Celution 700 System as a medical ...
35. RxNews Recap on Monday 11-02-09
(Home Page/Home Page)
... of Health, Labor and Welfare (MHLW) in Japan has granted final regulatory approval for KCI to market and sell its innovative V.A.C.® Therapy System in the country. Cytori Therapeutics Inc. (NASDAQ:CYTX) ...
36. RxNews Recap on Tuesday 10-27-09
(Home Page/Home Page)
... of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity.   Cytori Therapeutics, Inc., (NASDAQ:CYTX) will present and provide a webcast ...
Cytori Therapeutics (NASDAQ: CYTX) sent out an email alert to investors on 10/15/09 in the evening pertaining to results that were presented at the 7th Annual Meeting of the International Federation for ...
... 10/14/09. On 5/27/09, Cytori Therapeutics (NASDAQ: CYTX) ($3.50) announced that it completed enrollment in the first study to investigate adipose derived stem and regenerative cells in chronic heart disease. ...
39. FDA Calendar Extreme Trades: 85 Single Digit Stocks
(Premium Content/Subscriber Only Content)
... On 5/27/09, Cytori Therapeutics (NASDAQ: CYTX) ($3.50) announced that it completed enrollment in the first study to investigate adipose derived stem and regenerative cells in chronic heart disease. The ...
... for FUSILEV in this indication. Cytori Therapeutics Inc. (NASDAQ:CYTX), a company, engaged in the development and commercialization of some very promising stem and regenerative cell therapies for the ...
Cytori Therapeutics (NASDAQ: CYTX) has launched a new website at http://www.cellenrich.eu to help educate and raise awareness amongst patients and physicians on cell-enriched cosmetic surgery procedures. ...
... follow-up to my article earlier this week, Cytori’s (NASDAQ: CYTX) Cardiac Celution: Encouraging Interim Results, a 31-page PDF is now available at the BioMedReports.com research section in the medical ...
In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial ...
The stock research section of BioMedReports.com has been updated today to reflect the most recent corporate presentation for Cytori Therapeutics (NASDAQ:CYTX), following the Company’s presentation at the ...
SAN DIEGO--Cytori Therapeutics, Inc. (NASDAQ: CYTX) recently received a Notice of Allowance from the U.S. Patent and Trademark Office related to uses of the Celution® System for the treatment ...
... Senior Living BKD 9.96 -0.83 (-7.69%) 1.01B AEterna Zentaris Inc AEZS 2.17 -0.18 (-7.66%) 115.42M Cytori Therapeutics Inc CYTX 3.55 -0.29 (-7.55%) 121.02M Hemispherx ...
... engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. Currently trading at $1.60 with a market cap of $164.09M. Cytori Therapeutics ...
...  +1.39 (74.33%) 282.05M Hemispherx BioPharma, Inc HEB 3.75 +1.20 (47.06%) 319.23M Cytori Therapeutics Inc CYTX 4.54 +0.70 (18.23%) 154.76M Symyx Technologies, ...
... phase I interstitial 131I-chTNT-1/B MAb (Cotara) for the treatment of recurrent glioma - Tuesday, June 16: 12:30 PM - 2:00 PM - Room 701B. Cytori Therapeutics (NASDAQ: CYTX): On 5/27/09, CYTX announced ...
... I interstitial 131I-chTNT-1/B MAb (Cotara) for the treatment of recurrent glioma - Tuesday, June 16: 12:30 PM - 2:00 PM - Room 701B. Cytori Therapeutics (NASDAQ: CYTX): On 5/27/09, CYTX announced that ...

Get Free Email and Phone News Alerts

* Your email address:
* Preferred Format:
* Enter the security code shown:
 
Home | Privacy Policy
© 2010 BioMedReports.com. All rights reserved